Zevra Therapeutics Advances Rare Disease Portfolio with New Data and Strategic Expansion

Zevra Therapeutics continues to build its profile as a dedicated rare disease company. Recent clinical data presentations and a broadening commercial strategy highlight progress across its development pipeline. For investors who recall the company under its former name, KemPharm, these moves represent ongoing evolution into a specialized pharmaceutical entity.

The company presented new findings for its drug MIPLYFFA at the 22nd annual WORLDSymposium, held from February 2 to 6. Information shared on February 4, drawn from clinical studies and real-world analyses, supports the long-term safety and efficacy profile of the treatment for Niemann-Pick disease type C (NPC).

A key takeaway was the consistency of therapeutic outcomes across both pediatric and Read more...